Literature DB >> 11387345

Two splice variants of protein kinase B gamma have different regulatory capacity depending on the presence or absence of the regulatory phosphorylation site serine 472 in the carboxyl-terminal hydrophobic domain.

D Brodbeck1, M M Hill, B A Hemmings.   

Abstract

We have reported previously the cloning and characterization of human and mouse protein kinase B gamma (PKB gamma), the third member of the PKB family of second messenger-regulated serine/threonine kinases (Brodbeck, D., Cron, P., and Hemmings, B. A. (1999) J. Biol. Chem. 274, 9133--9136). Here we report the isolation of human and mouse PKB gamma 1, a splice variant lacking the second regulatory phosphorylation site Ser-472 in the hydrophobic C-terminal domain. Expression of PKB gamma 1 is low compared with PKB gamma, and it is regulated in different human tissues. We show that PKB gamma and PKB gamma 1 differ in their response to stimulation by insulin, pervanadate, peroxide, or okadaic acid. Activation of PKB gamma 1 requires phosphorylation at a single regulatory site Thr-305. Interestingly, this site is phosphorylated to a higher extent in PKB gamma compared with PKB gamma 1 upon maximal stimulation by pervanadate, and this is reflected in the respective specific kinase activities. Furthermore, upon insulin stimulation of transfected cells, PKB gamma 1 translocates to the plasma membrane to a lesser extent than PKB gamma. Taken together, these results suggest that phosphorylation of the hydrophobic motif at the extreme C terminus of PKB gamma may facilitate translocation of the kinase to the membrane and/or its phosphorylation on the activation loop site by phosphoinositide-dependent protein kinase-1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11387345     DOI: 10.1074/jbc.M104633200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury.

Authors:  Neeta Adhikari; Nathan Charles; Ute Lehmann; Jennifer L Hall
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

2.  AKTs/PKBs: molecular characterization, tissue expression and transcriptional responses to insulin and/or wortmannin in yellow catfish Pelteobagrus fulvidraco.

Authors:  Mei-Qin Zhuo; Ya-Xiong Pan; Kun Wu; Yi-Huan Xu; Li-Han Zhang; Zhi Luo
Journal:  Fish Physiol Biochem       Date:  2016-12-20       Impact factor: 2.794

3.  An Akt3 Splice Variant Lacking the Serine 472 Phosphorylation Site Promotes Apoptosis and Suppresses Mammary Tumorigenesis.

Authors:  Kimita Suyama; Jiahong Yao; Huizhi Liang; Outhiriaradjou Benard; Olivier D Loudig; Dulguun Amgalan; Wendy M McKimpson; Greg R Phillips; Jeffrey Segall; Yihong Wang; Susan Fineberg; Larry Norton; Richard N Kitsis; Rachel B Hazan
Journal:  Cancer Res       Date:  2017-10-16       Impact factor: 12.701

4.  Functional diversity of human protein kinase splice variants marks significant expansion of human kinome.

Authors:  Krishanpal Anamika; Nicolas Garnier; Narayanaswamy Srinivasan
Journal:  BMC Genomics       Date:  2009-12-22       Impact factor: 3.969

Review 5.  The Akt signaling pathway: an emerging therapeutic target in malignant melanoma.

Authors:  SubbaRao V Madhunapantula; Paul J Mosca; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2011-12-15       Impact factor: 4.742

6.  Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B.

Authors:  Michael P Scheid; Paola A Marignani; James R Woodgett
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

7.  Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

Authors:  Mitchell Cheung; Arati Sharma; SubbaRao V Madhunapantula; Gavin P Robertson
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

8.  In vivo role of the PIF-binding docking site of PDK1 defined by knock-in mutation.

Authors:  Barry J Collins; Maria Deak; J Simon C Arthur; Laura J Armit; Dario R Alessi
Journal:  EMBO J       Date:  2003-08-15       Impact factor: 11.598

Review 9.  The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.

Authors:  Subbarao V Madhunapantula; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2009-05-28       Impact factor: 4.693

10.  Alternative splicing controls myotonic dystrophy protein kinase structure, enzymatic activity, and subcellular localization.

Authors:  Derick G Wansink; René E M A van Herpen; Marga M Coerwinkel-Driessen; Patricia J T A Groenen; Brian A Hemmings; Bé Wieringa
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.